Allogene Therapeutics (ALLO) Times Interest Earned (2018 - 2026)
Allogene Therapeutics (ALLO) posted Times Interest Earned of -$0.45 for Q1 2026, up 87.15% sequentially from -$3.49 in Q4 2025, and up 90.31% YoY from -$0.24 in Q1 2025.
Allogene Therapeutics (ALLO) Times Interest Earned (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Times Interest Earned for 9 years, with the latest figure at -$0.45 in Q1 2026.
- Quarterly Times Interest Earned rose 90.31% year-over-year to -$0.45 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.85 (up 90.3% YoY) and the FY2025 annual result came in at -$16.23, down 2541.71% from the prior year.
- Times Interest Earned grew to -$0.45 in Q1 2026 per ALLO's latest filing, from -$3.49 in the prior quarter.
- Over five years, Times Interest Earned peaked at $14.18 in Q4 2023 and troughed at -$746.79 in Q4 2024.
- A 5-year average of -$50.01 and a median of -$2.33 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned soared 201.54% in 2023, then sank 5364.71% in 2024.
- Over 5 years, Times Interest Earned stood at -$13.97 in 2022, then soared by 201.54% to $14.18 in 2023, then tumbled by 5364.71% to -$746.79 in 2024, then soared by 99.53% to -$3.49 in 2025, then jumped by 87.15% to -$0.45 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$0.45, -$3.49, and -$1.85 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -0.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.47 |
| Mar 31, 2026 | -0.45 |
| Dec 31, 2025 | -3.49 |
| Sep 30, 2025 | -1.85 |
| Jun 30, 2025 | -2.22 |
| Mar 31, 2025 | -4.63 |
| Dec 31, 2024 | -746.79 |
| Sep 30, 2024 | -5.27 |
| Jun 30, 2024 | -0.57 |
| Mar 31, 2024 | -5.11 |
| Dec 31, 2023 | 14.18 |
| Sep 30, 2023 | -1.81 |
| Jun 30, 2023 | -2.22 |
| Mar 31, 2023 | -33.03 |
| Dec 31, 2022 | -13.97 |
| Sep 30, 2022 | -0.58 |
| Jun 30, 2022 | -2.33 |
| Mar 31, 2022 | -40.01 |
| Dec 31, 2021 | -1.46 |
| Sep 30, 2021 | -0.93 |